As the only TSLP antagonist developed to clinical stage, tezepelumab has been approved for the treatment of severe asthma and is being evaluated in multiple clinical trials for its efficacy in additional TSLP-mediated diseases, including severe chronic rhinosinusitis with nasal polyposis, chronic obstructive pulmonary disease, and chronic spontaneous urticaria. Here, TSLP is linked to asthma.